Drugs / AUR105
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05605119 | Nov 2022 → Mar 2024 | Hodgkins lymphoma, cancer, non-Hodgkin lymphoma | Aurigene Discovery Technologies Limited | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AUR105 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05605119 ↗ |
| Route | Oral | “Oral AUR105” NCT05605119 ↗ |